Key Insights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed with results

Key Signals

3Total

P 2 (2)

P 4 (1)

Not Yet Recruiting2

Recruiting1

Unknown1

Clinical Trials (4)

Showing 4 of 4 trials

Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy

The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer

Thymosin Alpha-1 for irAE Secondary to ICIs

Showing all 4 trials